CN113694248A - Embolism microsphere based on soluble starch and preparation and application thereof - Google Patents

Embolism microsphere based on soluble starch and preparation and application thereof Download PDF

Info

Publication number
CN113694248A
CN113694248A CN202111071157.XA CN202111071157A CN113694248A CN 113694248 A CN113694248 A CN 113694248A CN 202111071157 A CN202111071157 A CN 202111071157A CN 113694248 A CN113694248 A CN 113694248A
Authority
CN
China
Prior art keywords
microsphere
soluble
starch
embolism
embolism microsphere
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202111071157.XA
Other languages
Chinese (zh)
Other versions
CN113694248B (en
Inventor
张超
张琳雅
林润
张阳
杨越雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Yat Sen University
Original Assignee
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Yat Sen University filed Critical Sun Yat Sen University
Priority to CN202111071157.XA priority Critical patent/CN113694248B/en
Publication of CN113694248A publication Critical patent/CN113694248A/en
Application granted granted Critical
Publication of CN113694248B publication Critical patent/CN113694248B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/08Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0015Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0036Porous materials, e.g. foams or sponges
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0042Materials resorbable by the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2/00Processes of polymerisation
    • C08F2/32Polymerisation in water-in-oil emulsions
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F251/00Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow

Abstract

The invention provides an embolism microsphere based on soluble starch and preparation and application thereof. The embolism microsphere is prepared by soluble starch, an olefin polar monomer, an initiator and a cross-linking agent through an inverse suspension polymerization technology, wherein a continuous phase comprises an oil phase and a surfactant, and a dispersed phase comprises the soluble starch, the olefin polar monomer, the initiator and the cross-linking agent. According to the invention, the olefin polar monomer and the soluble starch are subjected to free radical grafting and then cross-linking to obtain the embolism microsphere, the embolism microsphere is rich in porous structure, pores extend towards the interior of the microsphere, so that the specific surface area of the embolism microsphere is larger, and the surface of the embolism microsphere has a large amount of hydrophilic polar groups, so that the embolism microsphere can generate electrostatic adsorption with a medicament, and a good medicament slow release effect of the embolism microsphere is realized. The embolism microsphere prepared by the invention has the drug loading of 191mg/g for doxorubicin hydrochloride and the entrapment rate of 96%, and effectively improves the drug loading and the entrapment rate of the starch embolism microsphere.

Description

Embolism microsphere based on soluble starch and preparation and application thereof
Technical Field
The invention belongs to the technical field of microsphere preparation. More particularly, relates to an embolism microsphere based on soluble starch and preparation and application thereof.
Background
The hepatic artery chemoembolization (TACE) plays an important role in the treatment of hepatocellular carcinoma, is the first choice treatment method for hepatocellular carcinoma in middle and late stages at present, and the key point of success of TACE is the design of an embolic agent, which blocks tumor blood vessels and blocks the nutrient source and oxygen supply of the tumor. The embolism microsphere is used as a novel drug delivery and embolism system, and is embolized to a lesion part through an artery by adsorbing chemotherapeutic drugs, so that the drugs are slowly released, and the anticancer effect is achieved. Theoretically, the drug-loaded embolization microsphere can not only realize higher local drug concentration and improve the treatment effect of TACE, but also reduce systemic toxicity, and is gradually the research focus and key point in the field.
According to the degradability of raw materials, the embolism microsphere can be divided into biodegradable microsphere and non-biodegradable microsphere, the starch microsphere is a typical biodegradable microsphere, can be gradually degraded under the action of serum amylase in blood flow, and is considered as an ideal targeted drug carrier due to the advantages of large specific surface area, high efficiency, low toxicity, no immunogenicity, directional slow-release delivery system and the like. The reverse emulsion method is the most common method for preparing starch microspheres, the synthesis process is simple, the reaction conditions are mild and easy to control, and the reaction reproducibility is good, for example, the heparin starch microsphere vascular embolization agent with the anti-tumor effect is prepared by the reverse emulsion method in patent CN201810440203.0, but the embolization agent has no porous structure on the surface, the corresponding specific surface area is smaller, and the drug loading rate and the encapsulation rate are limited directly.
Therefore, the search for a starch microsphere with a porous structure to increase the drug loading and encapsulation efficiency has considerable necessity in the technical field of embolic microsphere preparation.
Disclosure of Invention
Aiming at the defects of the existing starch microspheres, the invention provides an embolization microsphere based on soluble starch and preparation and application thereof, so that the porous structure of the embolization microsphere is realized, and the drug loading rate and the encapsulation efficiency of the embolization microsphere are improved.
The invention aims to provide an embolization microsphere based on soluble starch.
Another object of the present invention is to provide a method for preparing the above embolizing microspheres.
It is still another object of the present invention to provide the use of the above embolic microspheres as/in the preparation of a drug delivery vehicle.
The above purpose of the invention is realized by the following technical scheme:
the invention provides an embolism microsphere based on soluble starch, which is prepared by using soluble starch, an olefin polar monomer, an initiator and a cross-linking agent through an inverse suspension polymerization technology, wherein a continuous phase comprises an oil phase and a surfactant, and a dispersed phase comprises the soluble starch, the olefin polar monomer, the initiator and the cross-linking agent.
According to the invention, the infrared spectrum is utilized to analyze and identify the embolism microsphere of the soluble starch, and the characteristic peaks of carboxyl and starch are found to appear at the same time, which indicates that the preparation method of the invention can successfully introduce carboxyl into the starch microsphere; the embolization microsphere is characterized by adopting an optical microscope and a scanning electron microscope, the optical microscope shows that the embolization microsphere has uniform particle size distribution and good dispersibility, and the scanning electron microscope shows that the embolization microsphere has a smooth surface and is porous after freeze-drying, so that the embolization microsphere has a large specific surface area and can effectively realize high drug loading and high encapsulation rate; in addition, the invention also utilizes a hemolysis experimental data graph to carry out quantitative calculation, finds that the hemolysis rate of the embolism microsphere is lower than 5 percent, accords with the national standard, shows that the embolism microsphere can not cause obvious hemolysis and has biological safety.
According to the invention, the olefin polar monomer and the soluble starch are subjected to free radical grafting and then cross-linking to obtain the embolism microsphere, the embolism microsphere is rich in porous structure, pores extend towards the interior of the microsphere, so that the specific surface area of the embolism microsphere is larger, and the surface of the embolism microsphere has a large amount of hydrophilic polar groups, so that the embolism microsphere can generate electrostatic adsorption with a medicament, and a good medicament slow release effect of the embolism microsphere is realized. The embolism microsphere prepared by the invention has the drug loading of 191mg/g for doxorubicin hydrochloride and the entrapment rate of 96%, and effectively improves the drug loading and the entrapment rate of the starch embolism microsphere.
Preferably, the mass ratio of the soluble starch, the olefin polar monomer, the initiator and the cross-linking agent is 10: 5-10: 0.1-0.3: 0.1 to 0.2.
Most preferably, the mass ratio of the soluble starch, the olefin polar monomer, the initiator and the cross-linking agent is 10: 10: 0.2: 0.1, see example 1.
Preferably, the olefin polar monomer comprises one or more of acrylic acid, methacrylic acid or 2-acrylamide-2-methylpropanesulfonic acid.
Most preferably, the olefinic polar monomer is acrylic acid, see example 1.
Preferably, the soluble starch comprises one or more of soluble corn starch, soluble tapioca starch, soluble potato starch or soluble sweet potato starch.
Preferably, the initiator comprises one or more of sodium persulfate, ammonium persulfate or potassium persulfate.
Preferably, the crosslinking agent comprises one or more of epichlorohydrin, N' -methylene-bisacrylamide, sodium trimetaphosphate or glutaraldehyde.
Preferably, the oil phase comprises one or more of n-hexane, liquid paraffin, vegetable oil, kerosene or cyclohexane.
Preferably, the surfactant comprises one or more of Span 80, tween 80, Span 60 or tween 60.
Preferably, the mass ratio of the soluble starch, the oil phase and the surfactant is 1: 10-20: 0.02 to 0.5.
Most preferably, the mass ratio of the soluble starch, the oil phase and the surfactant is 1: 15: 0.4, see example 1.
The invention also provides a preparation method of the embolism microsphere, which comprises the following steps:
s1, mixing an olefin polar monomer, an initiator, a cross-linking agent and a soluble starch solution to obtain a dispersed phase;
s2, mixing and heating the oil phase and the surfactant to obtain a continuous phase;
s3, adding the dispersed phase obtained in the step S1 into the continuous phase obtained in the step S2, heating, standing, cleaning and drying to obtain the embolism microsphere based on the soluble starch.
Preferably, the preparation method of the soluble starch solution is specifically to dissolve soluble starch in water, and then add sodium hydroxide aqueous solution to mix, so as to obtain the soluble starch solution.
Preferably, the heating in step S3 is heating at 70-90 ℃.
Further preferably, in the step S3, stirring is further performed during heating, and the rotation speed of stirring is 200 to 700 r/min.
Preferably, the heating in the step S4 is performed at 70-90 ℃ for 1-3 h.
Further preferably, in the step S4, stirring is further performed during heating, and the rotation speed of stirring is 200 to 700 r/min.
Preferably, the cleaning is performed by using an organic solvent and deionized water, specifically, the embolism microsphere is repeatedly washed by using the organic solvent, repeatedly washed by using the deionized water after centrifugation, and finally centrifuged.
Further preferably, the organic solvent is one or more of absolute ethyl alcohol, ethyl acetate, petroleum ether or acetone.
The invention effectively improves the drug loading rate and the encapsulation efficiency of the starch embolism microsphere, so the application of the embolism microsphere in the preparation of drug delivery carrier is also within the protection scope of the invention.
Preferably, the drug comprises doxorubicin hydrochloride.
The invention has the following beneficial effects:
1) according to the invention, the olefin polar monomer and the soluble starch are subjected to free radical grafting and then cross-linking to obtain the embolism microsphere, the embolism microsphere is rich in porous structure, pores extend towards the interior of the microsphere, so that the specific surface area of the embolism microsphere is larger, and the surface of the embolism microsphere has a large amount of hydrophilic polar groups, so that the embolism microsphere can generate electrostatic adsorption with a medicament, and a good medicament slow release effect of the embolism microsphere is realized. The embolism microsphere prepared by the invention has the drug loading of 191mg/g for doxorubicin hydrochloride and the entrapment rate of 96%, and effectively improves the drug loading and the entrapment rate of the starch embolism microsphere.
2) The particle size of the embolism microsphere is 50-500 microns, the embolism microsphere is mainly distributed between 100-300 microns, the size of the embolism microsphere is in accordance with the ideal size, the embolism microsphere is round and smooth, the surface is smooth, and the structure is stable.
3) The embolism microsphere has the advantages of biodegradability, biocompatibility, nontoxicity, no immunogenicity and the like, the hemolysis rate is lower than 5%, and the embolism microsphere conforms to the national standard, shows that the embolism microsphere can not cause obvious hemolysis and has biosafety.
4) The preparation method is simple, can be used for preparing a large amount of the compound in a short time, has high production efficiency and high industrial feasibility, and has good and wide application prospect.
Drawings
FIG. 1 is a graph comparing infrared absorption spectra.
Fig. 2 is a graph of the results of optical microscope scanning.
FIG. 3 is a scanning electron microscope result chart.
FIG. 4 is a graph of data from a hemolysis experiment.
Detailed Description
The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Unless otherwise indicated, reagents and materials used in the following examples are commercially available.
EXAMPLE 1 preparation of embolic microspheres based on soluble starch
Preparation of embolism microsphere
S1, dissolving 2g of soluble cassava starch in 20mL of water, adding 500 mu L of 0.2mol/L sodium hydroxide aqueous solution, mixing and dissolving to obtain a soluble cassava starch solution;
s2, stirring and mixing acrylic acid, ammonium persulfate and N, N' -methylene bisacrylamide with the soluble cassava starch solution obtained in the step S1 to obtain a dispersion phase; (the mass ratio of the soluble cassava starch to the acrylic acid to the ammonium persulfate to the N, N' -methylene bisacrylamide is 10: 10: 0.2: 0.1);
s3, mixing n-hexane and Span 80, heating to 85 ℃, and stirring at the rotating speed of 300r/min to obtain a continuous phase; (the mass ratio of the soluble cassava starch to the normal hexane to the Span 80 meets 1: 15: 0.4);
s4, adding the dispersed phase obtained in the step S2 into the continuous phase obtained in the step S3, continuously heating at 85 ℃, stirring at a rotating speed of 300r/min, standing for layering after 1h, washing an oil phase remained on the surface of the microsphere with ethyl acetate, washing and separating with deionized water, and drying to obtain the embolism microsphere based on the soluble starch.
Second, embolism microsphere structure and performance test
(1) The embolization microspheres obtained in this example and the soluble tapioca starch used as the raw material were analyzed and identified by infrared spectroscopy to obtain a comparison graph of the infrared absorption spectrum curve of fig. 1. As can be seen from FIG. 1, the infrared absorption spectrum curve of the embolization microsphere has characteristic peaks of carboxyl and starch at the same time, which indicates that the preparation method of the invention successfully introduces carboxyl into the starch microsphere.
(2) The embolization microspheres obtained in this example were characterized by an optical microscope and a scanning electron microscope to obtain fig. 2 and 3. As can be seen from FIG. 2, the particle size distribution of the embolism microsphere is uniform, and the dispersity is good; as can be seen from FIG. 3, the embolic microspheres have smooth surfaces and are porous after lyophilization; the specific surface area of the embolism microsphere is larger by combining with the figure 2 and the figure 3, which shows that the preparation method of the invention effectively realizes high drug loading and high encapsulation efficiency of the embolism microsphere.
(3) The embolized microspheres obtained in this example were subjected to a hemolysis test by first centrifuging fresh rat blood, collecting erythrocytes, and diluting with physiological saline to obtain a 10% erythrocyte suspension. Mixing normal saline and erythrocyte suspension according to the volume ratio of 1: 1 as a negative control group; taking deionized water and erythrocyte suspension according to the volume ratio of 1: 1 as a positive control group; the embolized microspheres were dispersed in the erythrocyte suspension at 1mg/mL, 3mg/mL, 5mg/mL, 10mg/mL, and 15mg/mL to prepare an experimental group. After the control group and the experimental group are incubated at 37 ℃ for 1h, the absorbance is detected at the wavelength of 540nm to obtain a hemolysis experiment data graph shown in figure 4, the hemolysis rate of the embolism microsphere is calculated to be lower than 5% according to the following formula, the national standard is met, and the embolism microsphere does not cause obvious hemolysis and has biological safety.
Percent of hemolysis (A)sample-A0.9%NaCl)×100/(ADI water-A0.9%NaCl)
EXAMPLE 2 preparation of embolic microspheres based on soluble starch
S1, dissolving 2g of soluble potato starch in 20mL of water, adding 500 mu L of 0.2mol/L sodium hydroxide aqueous solution, and mixing and dissolving to obtain a soluble potato starch solution;
s2, mixing methacrylic acid, sodium persulfate and sodium trimetaphosphate with the soluble potato starch solution obtained in the step S1 to obtain a dispersion phase; (the mass ratio of the soluble potato starch to the methacrylic acid to the sodium persulfate to the sodium trimetaphosphate is 10: 5: 0.3: 0.2);
s3, mixing the liquid paraffin and Span 60, heating to 85 ℃, and stirring at the rotating speed of 300r/min to obtain a continuous phase; (the mass ratio of the soluble potato starch, the liquid paraffin and the Span 60 meets 1: 20: 0.5);
s4, adding the dispersed phase obtained in the step S2 into the continuous phase obtained in the step S3, continuously heating at 85 ℃, stirring at a rotating speed of 300r/min, standing for layering after 1h, washing an oil phase remained on the surface of the microsphere with ethyl acetate, washing and separating with deionized water, and drying to obtain the embolism microsphere based on the soluble starch.
Example 3 preparation of embolic microspheres based on soluble starch
S1, dissolving 2g of soluble corn starch in 20mL of water, adding 500 mu L of 0.2mol/L sodium hydroxide aqueous solution, mixing and dissolving to obtain a soluble corn starch solution;
s2, stirring and mixing acrylic acid, potassium persulfate and sodium trimetaphosphate with the soluble corn starch solution obtained in the step S1 to obtain a dispersion phase; (the mass ratio of the soluble corn starch to the acrylic acid to the potassium persulfate to the sodium trimetaphosphate is 10: 10: 0.1: 0.1);
s3, mixing kerosene and Span 80, heating to 90 ℃, and stirring at the rotating speed of 200r/min to obtain a continuous phase; (the mass ratio of the soluble corn starch, the kerosene and the Span 80 meets 1: 10: 0.02);
s4, adding the dispersed phase obtained in the step S2 into the continuous phase obtained in the step S3, continuously heating at 85 ℃, stirring at a rotating speed of 300r/min, standing for layering after 1h, washing an oil phase remained on the surface of the microsphere with ethyl acetate, washing and separating with deionized water, and drying to obtain the embolism microsphere based on the soluble starch.
Example 4 preparation of embolic microspheres based on soluble starch
S1, dissolving 2g of soluble sweet potato starch in 20mL of water, adding 500 mu L of 0.2mol/L sodium hydroxide aqueous solution, and mixing and dissolving to obtain a soluble sweet potato starch solution;
s2, stirring and mixing acrylic acid, ammonium persulfate and N, N' -methylene bisacrylamide with the soluble sweet potato starch solution obtained in the step S1 to obtain a dispersion phase; (the mass ratio of the soluble sweet potato starch to the acrylic acid to the ammonium persulfate to the N, N' -methylene-bisacrylamide is 10: 6: 0.18: 0.14);
s3, mixing the vegetable oil and the Tween 80, heating to 70 ℃, and stirring at the rotating speed of 700r/min to obtain a continuous phase; (the mass ratio of the soluble sweet potato starch, the vegetable oil and the Tween 80 meets 1: 15: 0.4);
s4, adding the dispersed phase obtained in the step S2 into the continuous phase obtained in the step S3, continuously heating at 70 ℃, stirring at a rotating speed of 700r/min, standing for layering after 1h, washing an oil phase remained on the surface of the microsphere with ethyl acetate, washing and separating with deionized water, and drying to obtain the embolism microsphere based on the soluble starch.
Example 5A method for preparing embolic microspheres based on soluble starch
S1, dissolving 2g of soluble sweet potato starch in 20mL of water, adding 500 mu L of 0.2mol/L sodium hydroxide aqueous solution, and mixing and dissolving to obtain a soluble sweet potato starch solution;
s2, stirring and mixing acrylic acid, 2-acrylamide-2-methylpropanesulfonic acid, ammonium persulfate and epoxy chloropropane with the soluble sweet potato starch solution obtained in the step S1 to obtain a dispersion phase; (the mass ratio of the soluble sweet potato starch to acrylic acid: 2-acrylamide-2-methylpropanesulfonic acid, ammonium persulfate and epichlorohydrin satisfies 10: 7.5: 2.5: 0.25: 0.1);
s3, mixing cyclohexane and Tween 60, heating to 85 ℃, and stirring at the rotating speed of 300r/min to obtain a continuous phase; (the mass ratio of the soluble sweet potato starch, the cyclohexane and the Tween 60 meets 1: 15: 0.3);
s4, adding the dispersed phase obtained in the step S2 into the continuous phase obtained in the step S3, continuously heating at 90 ℃, stirring at a rotating speed of 200r/min, standing for layering after 1h, washing an oil phase remained on the surface of the microsphere with ethyl acetate, washing and separating with deionized water, and drying to obtain the embolism microsphere based on the soluble starch.
Comparative example 1
The preparation method is the same as that of example 1, except that the mass ratio of the soluble tapioca starch to acrylic acid in step S2 is 10: 2.5.
comparative example 2
The preparation method is the same as that of example 1, except that the mass ratio of the soluble tapioca starch to acrylic acid in step S2 is 10: 20.
comparative example 3
The preparation method of example 2 is the same, except that the mass ratio of the soluble potato starch to the methacrylic acid in step S2 is 10: 2.5.
comparative example 4
The preparation method of example 2 is the same, except that the mass ratio of the soluble potato starch to the methacrylic acid in step S2 is 10: 20.
comparative example 5
The preparation method is the same as that of example 5, except that the mass ratio of the soluble sweet potato starch to the acrylic acid and the 2-acrylamide-2-methylpropanesulfonic acid in step S2 is 10: 2.5: 1.
comparative example 6
The preparation method is the same as that of example 5, except that the mass ratio of the soluble sweet potato starch to the acrylic acid and the 2-acrylamide-2-methylpropanesulfonic acid in step S2 is 10: 10: 10.
comparative example 7
The same preparation method as in example 1 except that the heating temperature in steps S3 and S4 was 40 ℃.
Comparative example 8
The same preparation method as in example 1 except that the heating temperature in steps S3 and S4 was 120 ℃.
Comparative example 9
The same preparation method as that of example 1 except that the stirring speed in steps S3 and S4 was 100 r/min.
Comparative example 10
The same preparation method as that of example 1 except that the stirring speed in steps S3 and S4 was 900 r/min.
Examples of the experiments
Respectively dispersing 50mg of the embolization microspheres prepared in examples 1 to 5 and comparative examples 1 to 10 into 5mL of 2mg/mL doxorubicin hydrochloride solution, shaking at a rotation speed of 100rpm/min for 24h, and respectively calculating the drug loading rate and the encapsulation rate of the embolization microspheres according to the residual doxorubicin hydrochloride concentration in the solution, wherein the drug loading rate is the drug mass in the embolization microspheres/the quality of the embolization microspheres, and the encapsulation rate is the drug mass in the embolization microspheres/the drug input rate × 100%, and the results are shown in table 1:
TABLE 1
Figure BDA0003260371720000081
Figure BDA0003260371720000091
As can be seen from Table 1, the drug loading and encapsulation efficiency of examples 1-5 are both high, especially the best of example 1; the comparative examples 1 to 10 in which the types and the amounts of the raw materials or the experimental parameters were changed could not be used to prepare microspheres effectively, or could not be used as embolization microspheres in practical applications. The invention shows that the medicine carrying amount of the prepared embolism microsphere to the doxorubicin hydrochloride is up to 191mg/g, the entrapment rate is up to 96 percent, and the medicine carrying amount and the entrapment rate of the starch embolism microsphere are effectively improved by specifically controlling the type and the dosage of the raw materials and the parameters of each step.
In conclusion, the embolism microsphere prepared by the invention is rich in porous structure, the pores extend to the interior of the microsphere, so that the specific surface area of the embolism microsphere is larger, and the surface of the embolism microsphere is provided with a large number of hydrophilic polar groups, so that the embolism microsphere can generate electrostatic adsorption with a medicament, and a good medicament slow-release effect of the embolism microsphere is realized. The embolism microsphere prepared by the invention has the drug loading of 191mg/g for doxorubicin hydrochloride and the entrapment rate of 96%, and effectively improves the drug loading and the entrapment rate of the starch embolism microsphere.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.

Claims (10)

1. The embolism microsphere is characterized in that the embolism microsphere is prepared by soluble starch, an olefin polar monomer, an initiator and a cross-linking agent through an inverse suspension polymerization technology, wherein a continuous phase comprises an oil phase and a surfactant, and a disperse phase comprises the soluble starch, the olefin polar monomer, the initiator and the cross-linking agent.
2. The embolic microsphere of claim 1, wherein the mass ratio of the soluble starch, the olefinic polar monomer, the initiator and the cross-linking agent is 10: 5-10: 0.1-0.3: 0.1 to 0.2.
3. The embolic microsphere of claim 1, wherein the olefinic polar monomer comprises one or more of acrylic acid, methacrylic acid, or 2-acrylamido-2-methylpropanesulfonic acid.
4. The embolic microsphere of claim 1, wherein the soluble starch comprises one or more of soluble corn starch, soluble tapioca starch, soluble potato starch, or soluble sweet potato starch.
5. The embolic microsphere of claim 1, wherein the initiator comprises one or more of sodium persulfate, ammonium persulfate, or potassium persulfate.
6. The embolic microsphere of claim 1, wherein the cross-linking agent comprises one or more of epichlorohydrin, N' methylenebisacrylamide, sodium trimetaphosphate, or glutaraldehyde.
7. The embolization microsphere of claim 1, wherein the mass ratio of the soluble starch, the oil phase and the surfactant is 1: 10-20: 0.02 to 0.5.
8. A method for preparing the embolism microsphere of any one of claims 1 to 7, which is characterized by comprising the following steps:
s1, mixing an olefin polar monomer, an initiator, a cross-linking agent and a soluble starch solution to obtain a dispersed phase;
s2, mixing and heating the oil phase and the surfactant to obtain a continuous phase;
s3, adding the dispersed phase obtained in the step S1 into the continuous phase obtained in the step S2, heating, standing, cleaning and drying to obtain the embolism microsphere based on the soluble starch.
9. Use of an embolization microsphere according to any one of claims 1 to 7 as a drug delivery vehicle.
10. The use of claim 9, wherein the medicament comprises doxorubicin hydrochloride.
CN202111071157.XA 2021-09-13 2021-09-13 Embolism microsphere based on soluble starch and preparation and application thereof Active CN113694248B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111071157.XA CN113694248B (en) 2021-09-13 2021-09-13 Embolism microsphere based on soluble starch and preparation and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111071157.XA CN113694248B (en) 2021-09-13 2021-09-13 Embolism microsphere based on soluble starch and preparation and application thereof

Publications (2)

Publication Number Publication Date
CN113694248A true CN113694248A (en) 2021-11-26
CN113694248B CN113694248B (en) 2023-03-17

Family

ID=78660266

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111071157.XA Active CN113694248B (en) 2021-09-13 2021-09-13 Embolism microsphere based on soluble starch and preparation and application thereof

Country Status (1)

Country Link
CN (1) CN113694248B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114057940A (en) * 2021-12-02 2022-02-18 中山大学 Biodegradable carbomer polymer microsphere with core-shell structure as well as preparation method and application thereof
CN114106252A (en) * 2021-12-13 2022-03-01 科睿驰(深圳)医疗科技发展有限公司 Color-developing embolism microsphere and preparation method thereof
CN114377191A (en) * 2022-01-18 2022-04-22 上海方润介入器械有限公司 Degradable embolism microsphere and preparation method thereof
CN114392384A (en) * 2021-12-24 2022-04-26 河南驼人医疗器械研究院有限公司 Method for preparing high drug-loading rate embolism microsphere and collecting device
CN114392383A (en) * 2022-01-18 2022-04-26 上海方润介入器械有限公司 Degradable embolism microsphere and preparation method thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211165A1 (en) * 2000-03-24 2003-11-13 Jean-Marie Vogel Microspheres for active embolization
US20050142207A1 (en) * 2003-12-31 2005-06-30 Industrial Technology Research Institute Method for preparing polymeric microsphere by aqueous two phase emulsion process
CN101125225A (en) * 2007-08-10 2008-02-20 苏州迦俐生生物医药科技有限公司 Microsphere type embolic agent and preparation technology thereof
CN101670095A (en) * 2009-04-13 2010-03-17 北京大学 Pharmaceutical composition for treating embolism and preparation method thereof
CN101695477A (en) * 2009-10-21 2010-04-21 甘肃农业大学 Method for preparing potato starch medicament carrier microspheres
CN101716349A (en) * 2009-12-16 2010-06-02 北京大学 Medicine composite used for embolotherapy and acesodyne and preparation method thereof
CN102603976A (en) * 2012-02-26 2012-07-25 河南工业大学 Preparation method of quaternary phosphonium cation starch microspheres
WO2014036681A1 (en) * 2012-09-04 2014-03-13 西能化工科技(上海)有限公司 Heat-expandable microspheres, preparation method and use thereof
CN103977458A (en) * 2014-05-28 2014-08-13 南京弗来明医疗器械有限公司 Polyhydroxyl polymer embolized microsphere and preparation process thereof
CN104177642A (en) * 2014-08-13 2014-12-03 浙江大学 Expanded bed adsorption matrix and preparation method thereof
CN108070060A (en) * 2017-12-29 2018-05-25 广州瀚东新材料科技有限公司 A kind of microballoon powder of the high cross-linked polymer of micron order and its preparation method and application
CN108620004A (en) * 2018-05-14 2018-10-09 河南工业大学 A kind of starch/PVA complex microspheres and preparation method thereof
CN109422886A (en) * 2017-08-22 2019-03-05 中国石油化工股份有限公司 A kind of anion doped spherex material and its preparation method and application
CN110201215A (en) * 2019-06-11 2019-09-06 科睿驰(深圳)医疗科技发展有限公司 A kind of gradient crosslinked high resiliency embolism microball and its preparation process

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211165A1 (en) * 2000-03-24 2003-11-13 Jean-Marie Vogel Microspheres for active embolization
US20050142207A1 (en) * 2003-12-31 2005-06-30 Industrial Technology Research Institute Method for preparing polymeric microsphere by aqueous two phase emulsion process
CN101125225A (en) * 2007-08-10 2008-02-20 苏州迦俐生生物医药科技有限公司 Microsphere type embolic agent and preparation technology thereof
CN101670095A (en) * 2009-04-13 2010-03-17 北京大学 Pharmaceutical composition for treating embolism and preparation method thereof
CN101695477A (en) * 2009-10-21 2010-04-21 甘肃农业大学 Method for preparing potato starch medicament carrier microspheres
CN101716349A (en) * 2009-12-16 2010-06-02 北京大学 Medicine composite used for embolotherapy and acesodyne and preparation method thereof
CN102603976A (en) * 2012-02-26 2012-07-25 河南工业大学 Preparation method of quaternary phosphonium cation starch microspheres
WO2014036681A1 (en) * 2012-09-04 2014-03-13 西能化工科技(上海)有限公司 Heat-expandable microspheres, preparation method and use thereof
CN103977458A (en) * 2014-05-28 2014-08-13 南京弗来明医疗器械有限公司 Polyhydroxyl polymer embolized microsphere and preparation process thereof
WO2015179997A1 (en) * 2014-05-28 2015-12-03 南京弗来明医疗器械有限公司 Polyhydroxyl polymer embolic microsphere and preparation process therefor
CN104177642A (en) * 2014-08-13 2014-12-03 浙江大学 Expanded bed adsorption matrix and preparation method thereof
CN109422886A (en) * 2017-08-22 2019-03-05 中国石油化工股份有限公司 A kind of anion doped spherex material and its preparation method and application
CN108070060A (en) * 2017-12-29 2018-05-25 广州瀚东新材料科技有限公司 A kind of microballoon powder of the high cross-linked polymer of micron order and its preparation method and application
CN108620004A (en) * 2018-05-14 2018-10-09 河南工业大学 A kind of starch/PVA complex microspheres and preparation method thereof
CN110201215A (en) * 2019-06-11 2019-09-06 科睿驰(深圳)医疗科技发展有限公司 A kind of gradient crosslinked high resiliency embolism microball and its preparation process

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
LOUGUET S等: "Poly(ethylene glycol) methacrylate hydrolyzable microspheres for transient vascular embolization", 《ACTA BIOMATERIALIA》 *
凌洁等: "交联淀粉微球的反相悬浮合成及成粒机理", 《西安航空技术高等专科学校学报》 *
姚少芳等: "交联共聚淀粉微球对阿司匹林吸附性能的研究", 《贵阳医学院学报》 *
彭司勋等: "《中国药学年鉴2017 第33卷》", 30 April 2019, 北京:中国医药科技出版社 *
朱立平: "反相悬浮聚合制备功能聚合物微球", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 *
袁惠燕等: "离子交换型栓塞微球及其载平阳霉素的制备与性质研究", 《北京大学学报(医学版)》 *
问娟娟: "淀粉微球的制备及其研究进展", 《黑龙江科技信息》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114057940A (en) * 2021-12-02 2022-02-18 中山大学 Biodegradable carbomer polymer microsphere with core-shell structure as well as preparation method and application thereof
CN114057940B (en) * 2021-12-02 2023-11-03 中山大学 Biodegradable carbomer core-shell structure polymer microsphere and preparation method and application thereof
CN114106252A (en) * 2021-12-13 2022-03-01 科睿驰(深圳)医疗科技发展有限公司 Color-developing embolism microsphere and preparation method thereof
CN114106252B (en) * 2021-12-13 2022-11-08 科睿驰(深圳)医疗科技发展有限公司 Color-developing embolism microsphere and preparation method thereof
CN114392384A (en) * 2021-12-24 2022-04-26 河南驼人医疗器械研究院有限公司 Method for preparing high drug-loading rate embolism microsphere and collecting device
CN114377191A (en) * 2022-01-18 2022-04-22 上海方润介入器械有限公司 Degradable embolism microsphere and preparation method thereof
CN114392383A (en) * 2022-01-18 2022-04-26 上海方润介入器械有限公司 Degradable embolism microsphere and preparation method thereof

Also Published As

Publication number Publication date
CN113694248B (en) 2023-03-17

Similar Documents

Publication Publication Date Title
CN113694248B (en) Embolism microsphere based on soluble starch and preparation and application thereof
CN103341172B (en) Dual-hole polysaccharide microspheres, preparation method and purpose thereof
EP3050902B1 (en) Process for producing porous cellulose beads using alkali aqueous solution, and porous cellulose beads produced by this process
CN103374143B (en) A kind of super large pore polymer microsphere and preparation method thereof
Yao et al. Microcapsules/microspheres related to chitosan
CN110662604A (en) Polymeric sorbents, preparation and uses thereof
JP6889265B2 (en) Chromatographic medium to which microspheres are bound, and a method for producing the same
CN106268703A (en) DNA immunization adsorbent and preparation method thereof
CN110327894A (en) A kind of blood purification polymer microsphere of high adsorption capacity and preparation method thereof
CN112023904B (en) Quickly synthesized adsorbent PACP-MnO2Nano microsphere and preparation method and application thereof
CN103205081A (en) Preparation method for temperature-sensitive chitosan-based polyelectrolyte composite micelle
JP2016153449A (en) Method for manufacturing porous cellulose particle
Lu et al. Preparation and characterization of molecularly imprinted poly (hydroxyethyl methacrylate) microspheres for sustained release of gatifloxacin
WO2016167268A1 (en) Method for producing porous cellulose beads, and adsorbent using same
JP6440320B2 (en) Method for producing porous cellulose beads and adsorbent using the same
CN102051001B (en) Core-shell structure compound gel microsphere and preparation method thereof
CN117101616A (en) Molecularly imprinted polymer adsorption material based on metal-organic framework, and preparation method and application thereof
JPS6233539A (en) Urea adsorbent
CN113896910B (en) Nano starch-based microgel microspheres and preparation method and application thereof
CN1887273A (en) Prepn process of polysaccharide vitreous particle
CN114432251B (en) Starch-sodium alginate embolism microsphere capable of carrying medicine and preparation method and application thereof
CN101402029B (en) Homogeneous crosslinking beta-cyclodextrin/wolfram carbine composite microsphere and method of producing the same
EP3059251B1 (en) Method for manufacturing porous cellulose beads
CN113801268B (en) Preparation method of chitosan modified acrylic-based microspheres
JP3021641B2 (en) Improved cellulose chromatography support

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant